Heron Therapeutics, Inc.

Total Valuation

Heron Therapeutics, Inc. carries a market capitalization of 75.37M, placing it among publicly traded companies globally. Its enterprise value stands at 238.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Heron Therapeutics, Inc. currently has 188.58M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 0.93, and the price-to-book ratio stands at -0.07.

Enterprise Valuation

The EV/Sales ratio of 1.58 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 561.78 provides insight into valuation relative to core operating earnings.

Financial Position

Heron Therapeutics, Inc. maintains a current ratio of 2.53, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Stock Price Statistics

Heron Therapeutics, Inc.'s stock has declined approximately -75.14583% over the past 52 weeks. The 50-day moving average sits at 0.60, while the 200-day moving average is 1.03.

Income Statement

Over the trailing twelve months, Heron Therapeutics, Inc. generated 150.71M in revenue and converted that into -30.94M in net income, yielding earnings per share of -0.18. EBITDA reached -8.16M, while operating income came in at -10.46M.

Balance Sheet

Heron Therapeutics, Inc. holds 44.78M in cash and equivalents against 141.63M in total debt, resulting in a net debt position of 115.52M. Total book value stands at -1.95B, with working capital of 138.47M providing operational flexibility.

Cash Flow

Heron Therapeutics, Inc. produced -20.26M in operating cash flow over the past twelve months. After subtracting -599,000.00 in capital expenditures, free cash flow totaled -20.86M - equivalent to -0.12 per share.

Margins

Heron Therapeutics, Inc. operates with a gross margin of 71.12, reflecting its pricing power and cost economics. The operating margin of -6.94 and net profit margin of -20.53 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Heron Therapeutics, Inc.'s most recent stock split took place on January 13, 2014 with a 20:1 split ratio.

Scores

Heron Therapeutics, Inc. posts an Altman Z-Score of -9.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.